Boston CEO
October 27-28, 2025
Mandarin Oriental Hotel, Boston
Join Longwood Healthcare Leaders this fall as top BioPharma executives convene at the Mandarin Oriental, Boston for off-the-record discussions and top tier networking with BioPharma CEOs, heads of research and development, life science investors, and leading academics.
Highlights
Boston CEO is co-hosted with leaders in the industry. See testimonials and highlights from speakers and attendees including MA Governor Maura Healey, Boston Mayor Michelle Wu, George Yancopoulos (CSO, Regeneron), Fiona Marshall (President, NIBR), Sally Kornbluth (President, MIT), Robert Plenge (Chief Research Officer, BMS), among others.
Boston CEO Co-Hosts
Boston CEO is co-hosted alongside leaders in the industry.
Featured Speakers
Celebrated Academics
World-Class BioPharma CEOs
Renowned Researchers
Biotech Luminaries
Top Strategy Executives
Key Current & Former Government Officials
Blue-Chip Investors
Agenda
Monday, October 27, 2025
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund
8:00 am
R&D COLLABORATION
Uli Bialucha, CSO, Xilio Therapeutics
Ben Ebert, CEO, Dana-Farber Cancer Institute
Oscar Izeboud, CEO, Scenic Biotech
Nancy Whiting, CEO, Recludix
Moderator: Markus Haeberlein, EVP, Discovery Science, Parabilis
8:30 am
TRANSLATING SCIENCE INTO MEDICINE
Giulio Draetta, CSO, MD Anderson
Susan Hockfield, President Emerita, MIT
Greg Petsko, Professor, Neurology, Harvard Medical School
Greg Verdine, Executive Chair, VidaVinci
9:00 am
REGULATORY, INDUSTRY & GOVERNANCE ROUNDTABLE
Jake Auchincloss, Congressman, Massachusetts
Peter Marks, former Director, CBER, FDA
Moncef Slaoui, former Head, Operation Warp Speed; former Head R&D, GSK
9:20 am
FIRESIDE CHAT
Marc Casper, CEO, Thermo Fisher Scientific
9:40 am
NETWORKING BREAK
10:10 am
ADVANCES IN CLINICAL TRIALS
David Lucchino, CEO, Brenig Therapeutics
Catherine Sabatos-Peyton, CEO, Larkspur Biosciences
Sarah Sheikh, Head, Global Development & Head, Neuroscience Therapeutic Area, Takeda
Alexis Wallace, CEO, Thrombolytic Science
10:40 am
POSITIONING FOR COMMERCIAL SUCCESS
Sharon Benzeno, CCO, Adaptive Biotechnologies
Keting Chu, CEO, Bluejay Therapeutics
Tolga Tanguler, CCO, Alnylam
Scott Weintraub, SVP, US Business, Alexion, AstraZeneca Rare Disease
Moderator: Robert Stanislaro, Senior Managing Director, FTI Consulting
11:10 am
EXPANDING PLATFORM POTENTIAL
Margo Georgiadis, CEO, Montai Therapeutics
Mathai Mammen, CEO, Parabilis
Raj Prasad, CFO, CRISPR Therapeutics
Joanne Smith-Farrell, CEO, Be Bio
Moderator: Mat Pletcher, CSO, Weaver
11:40 am
GUBERNATORIAL KEYNOTE
Maura Healey, Governor, Massachusetts
Moderator: Christoph Westphal, General Partner, Longwood Fund
12:00 pm
NETWORKING LUNCHEON
1:00 pm
NAVIGATING THE REGULATORY LANDSCAPE
Peter Hutt, General Counsel (former), FDA
Thomas Lönngren, Executive Director (former), EMA
Lisa Ricciardi, CEO, Cognition Therapeutics
1:30 pm
NAVIGATING PARTNERSHIPS ACROSS BORDERS
Mark Barrett, CBO, Madrigal Pharmaceuticals
Philippe Lopes-Fernandes, CBO, Ipsen
Moderator: Zhen Su, CEO, Marengo Therapeutics
2:00 pm
MANAGING THE RUNWAY
Brant Binder, CEO, Bonito Biosciences
David Hung, CEO, Nuvation Bio
Rachel Humphrey, CEO, Normunity
Daphne Karydas, President & CFO, Flare Therapeutics
Moderator: Brian McVeigh, CEO, Code Bio
2:30 pm
DRIVING PRODUCTIVITY IN R&D
Pedro Lichtinger, CEO, Starton Therapeutics
Tarek Samad, SVP, Global Head, Research, Lundbeck
Morten Sogaard, SVP, Astellas Innovation Lab
Lara Sullivan, CEO, Pyxis Oncology
Moderator: Sekhar Naik, CEO, MResult
2:50 pm
NETWORKING BREAK
3:20 pm
FIRESIDE CHAT
Bob Langer, Koch Institute Professor, MIT; Co-Founder, Moderna
Tim Springer, Latham Family Professor, Harvard; Co-Founder, Moderna
Moderator: Christoph Westphal, General Partner, Longwood Fund
3:40 pm
ENSURING HEALTH EQUITY AND PATIENT ACCESS
Julian Adams, CEO, Stand Up To Cancer
John Glasspool, CEO, VarmX
Anne Klibanski, CEO, Mass General Brigham
4:10 pm
RNAi REVOLUTION: THE ALNYLAM STORY
Pushkal Garg, Chief R&D Officer, Alnylam
Phil Sharp, Koch Institute Professor, MIT; Scientific Co-Founder Biogen/Alnylam
Moderator: Christoph Westphal, General Partner, Longwood Fund
4:30 pm
INVESTOR OUTLOOK
Jessica Chutter, Managing Director, Vice Chair, Biotechnology Investment Banking, Morgan Stanley
Mike Ehlers, Entrepreneur Partner, MPM BioImpact
Jason Fuller, Partner, Deerfield
Dan Omstead, CEO, Tekla Capital Management
Tuesday, October 28, 2025
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
Aleks Radovic-Moreno, Partner, Longwood Fund
8:00 am
BIOPHARMA PIPELINE SOURCING
Charlotte Allerton, SVP, Head, Discovery & Early Development, Pfizer
Robert Baloh, Global Head of Neuroscience, Novartis Biomedical Research
Najat Khan, Chief R&D Officer & CCO, Recursion
8:30 am
PATIENT-CENTRIC DEVELOPMENT
Asa Abeliovich, CEO, Leal Therapeutics
Al Gianchetti, CEO, XyloCor
Bill Haney, CEO, Skyhawk Therapeutics
Maureen Hillenmeyer, CEO, Hexagon Bio
8:50 am
DEVELOPING AN EFFECTIVE BOARD
Harvey Berger, former CEO, Ariad
Jim Geraghty, Chair, OMass Therapeutics
Chris Loose, CEO, Progentos Therapeutics
9:20 am
CROSSROADS OF SCIENCE AND POLICY: SUSTAINING THE ENGINE OF INNOVATION
Sally Kornbluth, President, MIT
9:50 am
NETWORKING BREAK
10:20 am
ACCELERATING DRUG DISCOVERY
Joe Bolen, CEO, Orna Therapeutics
Marion Dorsch, CSO, Atavistik Bio
Skip Virgin, Distinguished Fellow, AI Drug Discovery & Development, Gates Foundation
Quinn Wills, CEO, Ochre Bio
Moderator: John Lepore, CEO, ProFound Therapeutics
10:50 am
ADVANCING LATE-STAGE ASSETS
Bill Lundberg, CEO, Merus
James Mackay, CEO, Crystalys Therapeutics
Richard Paulson, CEO, Karyopharm
11:20 am
FIRESIDE CHAT
Thomas Schinecker, CEO, Roche
11:40 am
TARGETED LICENSING & ACQUSITIONS
Susan Hill, CEO, Mestag Therapeutics
Stu Mackey, Global Head, BD, Daiichi Sankyo
Sekar Kathiresan, CEO, Verve Therapeutics
Moderator: Tim Ehrlich, Partner, Gunderson Dettmer
12:10 pm
NETWORKING LUNCHEON
1:00 pm
FIRESIDE CHAT: PHARMA R&D
Priya Singhal, EVP, Head, Development, Biogen
1:30 pm
ECOSYSTEM OF EXTERNAL INNOVATION
Maria Fardis, CEO, Lassen Therapeutics
Miguel Fernández Alcalde, President, EMD Serono
Brian Foard, EVP, Global Specialty Care, Sanofi
2:00 pm
ACCELERATING DRUG DEVELOPMENT
Lotte Bjerre Knudsen, Chief Scientific Advisor & Head, Innovation & Data Experimentation Advancement, Novo Nordisk
Marianne De Backer, CEO, Vir Bio
Bari Kowal, SVP & Head, Development Operations & Portfolio Management, Regeneron
Phil Vickers, CEO, Solu Therapeutics
Moderator: Yiannis Kiachopoulos, CEO, Causaly
2:30 pm
ADAPTING TO BUSINESS OPPORTUNITIES IN ASIA
Stewart Geary, CMO, Esai
2:50 pm
NETWORKING BREAK
3:20 pm
ENSURING GLOBAL ACCESS
Rachid Izzar, EVP of Global Product Strategy & Commercialization, Biogen
Stephanie Oestrich, Managing Director, Myeloma Investment Fund
Tarek Rabah, CEO, Otsuka North America
Moderator: Vikram Karnani, CEO, Collegium Pharmaceutical
3:50 pm
FIRESIDE CHAT
Dave Moore, EVP, US Operations & President Novo Nordisk, Inc.
4:10 pm
THE EVOLVING DEAL-MAKING LANDSCAPE
Janice Chen, CTO, Mammoth Biosciences
Vijay Iyengar, EVP, Global Medical Affairs, Product & Partnership Strategy, Incyte
Moderator: Kyle Lefkoff, General Partner, Boulder Ventures
4:40 pm
EVALUATING INVESTMENT RISK
Peter Bisgaard, Managing Director, Pivotal Life Science
Ansbert Gadicke, Managing Partner, MPM BioImpact
5:10 pm
COCKTAIL RECEPTION
Speaking Faculty
